A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Infectious Disease Clinical Trial

Official title:

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Subjects With Impaired Renal Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01275170
• Other study ID #: 7655-005
• Status: Completed
• Phase: Phase 1
• Start date: January 28, 2011
• Est. completion date: March 5, 2012

Study information

• Verified date: May 2020
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 2-part study of the pharmacokinetics (PK) of MK-7655. In Part I, the PK of a single 125 mg dose of MK-7655 given in combination with 250 mg of PRIMAXIN® (imipenem + cilastatin) will be determined in participants with impaired renal function and matched control participants. In Part II, the potential for renal insufficiency to affect non-renal clearance mechanisms will be investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: March 5, 2012
• Est. primary completion date: March 5, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria

• Participants of reproductive potential (male or female) must be willing to use contraception.

• Body Mass Index (BMI) =40 kg/m^2

• Weight >60 kg at screening visit

• No clinically significant abnormality on electrocardiogram (ECG) at screening visit and/or prior to administration of the initial dose of study drug

• Panels A-D: smokers will be limited to no more that 10 cigarettes per day.

• Panels E-H: nonsmoker or has not used nicotine for at least 6 months

• In good health (stable health for participants with renal impairment)

Exclusion criteria

• Pregnant or breastfeeding.

• History of recent stroke, chronic seizures, or major neurological disorder

• History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, immunological, respiratory, or genitourinary abnormalities or diseases

• History of malignant neoplastic disease. Exceptions: (1) adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix; (2) other malignancies that have been successfully treated =10 years prior to the screening visit

• Panels A-D: Use of any medication (prescription or non-prescription) or herbal remedies (such as St. John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug to the post study visit

• Panels E-H: Use of any medication (prescription or non-prescription) or herbal remedies (such as St. John's Wort [Hypericum perforatum]) that are inhibitors or inducers of CYP1A2, CYP2C19, CYP34A, or substrates of CYP2C19, beginning approximately 2 weeks (or 5 half-lives) prior to administration of the probe cocktail, until the post-study visit

• Consumption of greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day

• Consumption of greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day

• Major surgery, donation or loss of 1 unit of blood (approximately 500 mL), or participation in another investigational study within 4 weeks prior to the screening visit

• History of multiple and/or severe allergies (including latex allergy), or prior anaphylactic reaction or intolerability to prescription or non-prescription drugs or food

• History of hypersensitivity to PRIMAXIN® IV or other beta lactam antibiotic (including but not limited to penicillins, cephalosporins, monobactams and carbapenems)

• Regular user (including recreational use of drugs [including alcohol]) within approximately 12 months of screening visit

• History of kidney removal and/or renal transplant

• History of Clostridium difficile colitis or known C. difficile colonization

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Infectious Disease
• Renal Insufficiency

Intervention

Drug:
• MK-7655
125 mg intravenous (IV) over 30 minutes as a single dose
• Imipenem + Cilastatin
250 mg IV over 30 minutes as a single dose
• Caffeine
Caffeine caplet, single 200 mg dose, orally
• Midazolam
Midazolam hcl syrup single 2.0 mg dose by mouth.
• Omeprazole
Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Bhagunde P, Colon-Gonzalez F, Liu Y, Wu J, Xu SS, Garrett G, Jumes P, Lasseter K, Marbury T, Rizk ML, Lala M, Rhee EG, Butterton JR, Boundy K. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolera — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Area Under the Plasma Concentration-time Curve From Dosing to Infinity (AUC0-inf) of MK-7655 in Combination With PRIMAXIN®	AUC0-8 is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Primary	Dialysis Clearance (CLD) of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)	The CLD of MK-7655 was determined in ESRD/HD participants for 4.5 hours during HD. The formula for calculating CLD was: CLd = (1-Hct)*QB*[(pre-dialyzer concentration - post-dialyzer concentration) / (pre-dialyzer concentration)] where QB=350 mL/min and Hct=hematocrit.	1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours postdose
Primary	Extraction Coefficient of MK-7655 in Participants With End-stage Renal Diseases Requiring Hemodialysis (ESRD/HD)	The extraction coefficient of MK-7655 was determined in ESRD/HD participants for 4.5 hours during HD. The formula for calculating extraction coefficient was: Extraction Coefficient = ABS[100*(post-dialyzer concentration - pre-dialyzer concentration) / pre-dialyzer concentration].	1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours postdose
Secondary	Part 1: Concentration at End of Infusion (Ceoi) of MK-7655 in Combination With PRIMAXIN®	Ceoi is the observed plasma drug concentration at the end of IV infusion.	At 0.5 hours postdose
Secondary	Part 1: Predicted Clearance (CLpred) of MK-7655 in Combination With PRIMAXIN®	CLpred is the predicted apparent total body clearance of drug.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Predicted Volume of Distribution During the Terminal Phase (VZpred) of MK-7655 in Combination With PRIMAXIN®	VZpred is the predicted volume of distribution during the terminal phase.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Time of Maximum Plasma Concentration (Tmax) of MK-7655 in Combination With PRIMAXIN®	Tmax is the time at which the highest plasma drug concentration was observed.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Apparent Plasma Half-life (t½) of MK-7655 in Combination With PRIMAXIN®	Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: AUC0-inf of Imipenem in Combination With MK-7655	Imipenem is 1 of the 2 constituents of PRIMAXIN®. AUC0-8 is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Ceoi of Imipenem in Combination With MK-7655	Imipenem is 1 of the 2 constituents of PRIMAXIN®. Ceoi is the observed plasma drug concentration at the end of IV infusion.	At 0.5 hours postdose
Secondary	Part 1: CLpred of Imipenem in Combination With MK-7655	Imipenem is 1 of the 2 constituents of PRIMAXIN®. CLpred is the predicted apparent total body clearance of drug.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: VZpred of Imipenem in Combination With MK-7655	Imipenem is 1 of the 2 constituents of PRIMAXIN®. VZpred is the predicted volume of distribution during the terminal phase.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Tmax of Imipenem in Combination With MK-7655	Tmax is the time at which the highest plasma drug concentration was observed.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Apparent t½ of Imipenem in Combination With MK-7655	Imipenem is 1 of the 2 constituents of PRIMAXIN®. Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: AUC0-inf of Cilastin in Combination With MK-7655	Cilastin is 1 of the 2 constituents of PRIMAXIN®. AUC0-8 is a measure of the mean (extrapolated) plasma drug concentration after dosing to infinity.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Ceoi of Cilastin in Combination With MK-7655	Cilastin is 1 of the 2 constituents of PRIMAXIN®. Ceoi is the observed plasma drug concentration at the end of IV infusion.	At 0.5 hours postdose
Secondary	Part 1: CLpred of Cilastin in Combination With MK-7655	Cilastin is 1 of the 2 constituents of PRIMAXIN®. CLpred is the predicted apparent total body clearance of drug.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: VZpred of Cilastin in Combination With MK-7655	Cilastin is 1 of the 2 constituents of PRIMAXIN®. VZpred is the predicted volume of distribution during the terminal phase.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Tmax of Cilastin in Combination With MK-7655	Tmax is the time at which the highest plasma drug concentration was observed.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Apparent t½ of Cilastin in Combination With MK-7655	Cilastin is 1 of the 2 constituents of PRIMAXIN®. Apparent t½ is the amount of time for the maximum drug concentration to decrease by 50%.	Predose and 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, and 14 hours postdose
Secondary	Part 1: Renal Clearance (CLR) of MK-7655 in Urine	CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.	Predose to 24 hours postdose
Secondary	Part 1: CLR of Imipenem in Urine	CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.	Predose to 24 hours postdose
Secondary	Part 1: CLR of Cilastin in Urine	CLR represents renal clearance in urine. Urine was collected for 24 hours postdose.	Predose to 24 hours postdose
Secondary	Part 2: Plasma AUC0-8 of Caffeine as a Probe Substrate of Cytochrome P450 Enzyme (CYP)1A2	Caffeine was selected as a substrate of CYP1A2. AUC0-8 was determined in participants with severe renal impairment and ESRD/HD participants.	Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose
Secondary	Part 2: Plasma AUC0-8 of Midazolam as a Probe Substrate of Cytochrome P450 Enzyme (CYP)3A4	Midazolam was selected as a substrate of CYP3A4. AUC0-8 was determined in participants with severe renal impairment and ESRD/HD participants.	Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose
Secondary	Part 2: Plasma AUC0-8 of Omeprazole as a Probe Substrate of Cytochrome P450 Enzyme (CYP)2C19	Omeprazole was selected as a substrate of CYP2C19. AUC0-8 was determined in participants with severe renal impairment and ESRD/HD participants.	Predose and 0.5, 1, 2,3, 4, 8, 12, and 24 hours postdose
Secondary	Parts 1 and 2: Percentage of Participants With =1 Adverse Events (AEs)	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.	Up to 14 days after the last dose of study drug in Part 2 (up to 11 weeks)